Solve Therapeutics, Inc. — Form D
Solve Therapeutics, Inc. of BELMONT, CA, a company, filed a Form D exempt-offering notice with the SEC on 2022-01-21. The offering totals $126.5M, of which $63.5M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-01-21
- Form: D
- Accession: 0001905252-22-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $126.5M
- Amount sold: $63.5M
- Remaining: $63.0M
- Investors: 11
- Date of first sale: 2021-12-17
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-430372
Issuer
- Name: Solve Therapeutics, Inc.
- CIK: 0001905252
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 1025 ALAMEDA DE LAS PULGAS, SUITE 122, BELMONT, CA, 94002
- Phone: (858) 357-4137
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| David Johnson | Director | Greenwood Village, CO |
| David Johnson | Executive Officer | Greenwood Village, CO |
| Daniel D McHugh | Director | Belmont, CA |
| Langdon Miller | Executive Officer | Belmont, CA |
| Clayton D Knox | Executive Officer | Belmont, CA |
| Robert D Mittendorff | Director | Belmont, CA |
| Alan Colowick | Director | Belmont, CA |
| Jason Pitts | Director | Belmont, CA |
| Peter Colabuono | Director | Belmont, CA |
Other filings by this issuer (2)
More